Home
Bjørn Tore Gjertsen's picture

Bjørn Tore Gjertsen

Professor
  • E-mailBjorn.Gjertsen@uib.no
  • Phone+47 55 97 29 68+47 415 66 248
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Selected publications
  • Engen, Caroline Benedicte Nitter; Hajjar, Ehsan; Gjertsen, Bjørn Tore. 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 17: 20-29. doi: 10.2174/1389201016666150930115024
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; McCormack, Emmet; Postema, Michiel; Gjertsen, Bjørn Tore; Gilja, Odd Helge. 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 139: 2092-2092. doi: 10.1121/1.4950209
  • Gavasso, Sonia; Gullaksen, Stein-Erik; Skavland, Jørn; Gjertsen, Bjørn Tore. 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 16: 579-589. doi: 10.1586/14737159.2016.1156531
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology. 34:e15703.
  • Leitch, Calum; Osdal, Tereza; Andresen, Vibeke; Molland, Maren Kristine Butler; Kristiansen, Silje Elisabeth; Nguyen, Nhi Xuan; Bruserud, Øystein; Gjertsen, Bjørn Tore; McCormack, Emmet. 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 7: 8105-8118. doi: 10.18632/oncotarget.6991
  • Sulen, Andre; Lygre, Stein Håkon Låstad; Hjelle, Sigrun Margrethe; Hollund, Bjørg Eli; Gjertsen, Bjørn Tore. 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports. 6:29060. doi: 10.1038/srep29060
  • Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin; Dreimane, Arta; Porkka, Kimmo; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Gruber, Franz; Stenke, Leif; Myhr-Eriksson, Kristina; Markevärn, Berit; Lübking, Anna; Vestergaard, Hanne; Udby, Lene; Bjerrum, Ole Weis; Persson, Inger; Mustjoki, Satu; Olsson-Strömberg, Ulla. 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30: 1853-1860. doi: 10.1038/leu.2016.121
  • Sulen, Andre; Gullaksen, Stein-Erik; Bader, Lucius; McClymont, David; Skavland, Jørn; Gavasso, Sonia; Gjertsen, Bjørn Tore. 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 113: 216-227. doi: 10.1016/j.phrs.2016.08.018
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 243: 172-181. doi: 10.1016/j.jconrel.2016.10.007
  • Helland, Øystein; Popa, Mihaela Lucia; Bischof, Katharina; Gjertsen, Bjørn Tore; McCormack, Emmet; Bjørge, Line. 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLoS ONE. 11:e0158208. doi: 10.1371/journal.pone.0158208
  • Sulen, Andre; Gjertsen, Bjørn Tore. 2016. Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability. Universitetet i Bergen.
  • Thielen, Noortje; Richter, Johan; Baldauf, Matthias; Barbany, Gisela; Fioretos, Thoas; Giles, Francis; Gjertsen, Bjørn Tore; Hochhaus, Andreas; Schuurhuis, Gerrit Jan; Sopper, Sieghart; Stenke, Leif; Thunberg, Sarah; Wolf, Dominik; Ossenkoppele, Gert; Porkka, Kimmo; Janssen, Jeroen; Mustjoki, Satu. 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 22: 4030-4038. doi: 10.1158/1078-0432.CCR-15-2791
  • Andresen, Vibeke; Erikstein, Bjarte Skoe; Mukherjee, Herschel; Sulen, Andre; Popa, Mihaela Lucia; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G.; Gjertsen, Bjørn Tore. 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 7:e2497: 1-14. doi: 10.1038/cddis.2016.392
  • Kontro, Mika; Kumar, Anil; Majumder, Muntasir Mamun; Eldfors, Samuli; Parsons, Alun; Pemovska, Tea; Saarela, Janna; Yadav, Bhagwan; Malani, Disha; Fløisand, Yngvar; Höglund, Martin; Remes, Kari Juhani; Gjertsen, Bjørn Tore; Kallioniemi, Olli; Wennerberg, Krister; Heckman, Caroline Akemi; Porkka, Kimmo. 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 31: 301-309. doi: 10.1038/leu.2016.222
  • Kotopoulis, Spiros; Stigen, Endre; Popa, Mihaela Lucia; Safont, Mireia Mayoral; Healey, Andrew; Kvåle, Svein; Sontum, Per; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 245: 70-80. doi: 10.1016/j.jconrel.2016.11.019
  • Sopper, Sieghart; Mustjoki, Satu; White, Deborah; Hughes, Timothy; Valent, Peter; Burchert, Andreas; Gjertsen, Bjørn Tore; Gastl, Günther; Baldauf, Matthias; Trajanoski, Zlatko; Giles, Frank; Hochhaus, Andreas; Ernst, Thomas; Schenk, Thomas; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert J.; Porkka, Kimmo; Wolf, Dominik. 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 35: 175-184. doi: 10.1200/JCO.2016.67.0893
  • Omsland, Maria; Bruserud, Øystein; Gjertsen, Bjørn Tore; Andresen, Vibeke. 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 8: 7946-7963. doi: 10.18632/oncotarget.13853
  • Rajala, Hanna L.M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Janssen, Jeroen; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu. 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143: 1543-1554. doi: 10.1007/s00432-017-2378-6
  • Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore. 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 102: 1361-1367. doi: 10.3324/haematol.2017.167080
  • Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela Lucia; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir Mamun; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn Tore; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline Akemi. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 130: 789-802. doi: 10.1182/blood-2016-02-699363
  • Reikvam, Håkon; Hovland, Randi; Forthun, Rakel Brendsdal; Erdal, Sigrid; Gjertsen, Bjørn Tore; Fredly, Hanne Kristin; Bruserud, Øystein. 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 17:630: 1-13. doi: 10.1186/s12885-017-3620-y
Journal articles
  • Forthun, Rakel Brendsdal; Aasebø, Elise; Rasinger, Josef Daiel; Bedringaas, Siv Lise; Berven, Frode; Selheim, Frode; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. doi: 10.1016/j.jprot.2017.11.014
  • Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore. 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 102: 1361-1367. doi: 10.3324/haematol.2017.167080
  • Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela Lucia; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir Mamun; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn Tore; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline Akemi. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 130: 789-802. doi: 10.1182/blood-2016-02-699363
  • Kontro, Mika; Kumar, Anil; Majumder, Muntasir Mamun; Eldfors, Samuli; Parsons, Alun; Pemovska, Tea; Saarela, Janna; Yadav, Bhagwan; Malani, Disha; Fløisand, Yngvar; Höglund, Martin; Remes, Kari Juhani; Gjertsen, Bjørn Tore; Kallioniemi, Olli; Wennerberg, Krister; Heckman, Caroline Akemi; Porkka, Kimmo. 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 31: 301-309. doi: 10.1038/leu.2016.222
  • Kotopoulis, Spiros; Stigen, Endre; Popa, Mihaela Lucia; Safont, Mireia Mayoral; Healey, Andrew; Kvåle, Svein; Sontum, Per; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 245: 70-80. doi: 10.1016/j.jconrel.2016.11.019
  • Omsland, Maria; Bruserud, Øystein; Gjertsen, Bjørn Tore; Andresen, Vibeke. 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 8: 7946-7963. doi: 10.18632/oncotarget.13853
  • Rajala, Hanna L.M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Janssen, Jeroen; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu. 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143: 1543-1554. doi: 10.1007/s00432-017-2378-6
  • Reikvam, Håkon; Hovland, Randi; Forthun, Rakel Brendsdal; Erdal, Sigrid; Gjertsen, Bjørn Tore; Fredly, Hanne Kristin; Bruserud, Øystein. 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 17:630: 1-13. doi: 10.1186/s12885-017-3620-y
  • Sopper, Sieghart; Mustjoki, Satu; White, Deborah; Hughes, Timothy; Valent, Peter; Burchert, Andreas; Gjertsen, Bjørn Tore; Gastl, Günther; Baldauf, Matthias; Trajanoski, Zlatko; Giles, Frank; Hochhaus, Andreas; Ernst, Thomas; Schenk, Thomas; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert J.; Porkka, Kimmo; Wolf, Dominik. 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 35: 175-184. doi: 10.1200/JCO.2016.67.0893
  • Andresen, Vibeke; Erikstein, Bjarte Skoe; Mukherjee, Herschel; Sulen, Andre; Popa, Mihaela Lucia; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G.; Gjertsen, Bjørn Tore. 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 7:e2497: 1-14. doi: 10.1038/cddis.2016.392
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 243: 172-181. doi: 10.1016/j.jconrel.2016.10.007
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology. 34:e15703.
  • Engen, Caroline Benedicte Nitter; Hajjar, Ehsan; Gjertsen, Bjørn Tore. 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 17: 20-29. doi: 10.2174/1389201016666150930115024
  • Gavasso, Sonia; Gullaksen, Stein-Erik; Skavland, Jørn; Gjertsen, Bjørn Tore. 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 16: 579-589. doi: 10.1586/14737159.2016.1156531
  • Helland, Øystein; Popa, Mihaela Lucia; Bischof, Katharina; Gjertsen, Bjørn Tore; McCormack, Emmet; Bjørge, Line. 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLoS ONE. 11:e0158208. doi: 10.1371/journal.pone.0158208
  • Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin; Dreimane, Arta; Porkka, Kimmo; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Gruber, Franz; Stenke, Leif; Myhr-Eriksson, Kristina; Markevärn, Berit; Lübking, Anna; Vestergaard, Hanne; Udby, Lene; Bjerrum, Ole Weis; Persson, Inger; Mustjoki, Satu; Olsson-Strömberg, Ulla. 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30: 1853-1860. doi: 10.1038/leu.2016.121
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; McCormack, Emmet; Postema, Michiel; Gjertsen, Bjørn Tore; Gilja, Odd Helge. 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 139: 2092-2092. doi: 10.1121/1.4950209
  • Leitch, Calum; Osdal, Tereza; Andresen, Vibeke; Molland, Maren Kristine Butler; Kristiansen, Silje Elisabeth; Nguyen, Nhi Xuan; Bruserud, Øystein; Gjertsen, Bjørn Tore; McCormack, Emmet. 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 7: 8105-8118. doi: 10.18632/oncotarget.6991
  • Sulen, Andre; Gullaksen, Stein-Erik; Bader, Lucius; McClymont, David; Skavland, Jørn; Gavasso, Sonia; Gjertsen, Bjørn Tore. 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 113: 216-227. doi: 10.1016/j.phrs.2016.08.018
  • Sulen, Andre; Lygre, Stein Håkon Låstad; Hjelle, Sigrun Margrethe; Hollund, Bjørg Eli; Gjertsen, Bjørn Tore. 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports. 6:29060. doi: 10.1038/srep29060
  • Thielen, Noortje; Richter, Johan; Baldauf, Matthias; Barbany, Gisela; Fioretos, Thoas; Giles, Francis; Gjertsen, Bjørn Tore; Hochhaus, Andreas; Schuurhuis, Gerrit Jan; Sopper, Sieghart; Stenke, Leif; Thunberg, Sarah; Wolf, Dominik; Ossenkoppele, Gert; Porkka, Kimmo; Janssen, Jeroen; Mustjoki, Satu. 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 22: 4030-4038. doi: 10.1158/1078-0432.CCR-15-2791
  • Bruserud, Øystein; Reikvam, Håkon; Fredly, Hanne Kristin; Skavland, Jørn; Hagen, Karen Marie; Hoang, Tuyen; Brenner, Annette; Kadi, Amir; Astori, Audrey; Gjertsen, Bjørn Tore; Pendino, Frederic. 2015. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 6: 2794-2811.
  • Gjertsen, Bjørn Tore; Schöffski, Patrick. 2015. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 29: 11-19. doi: 10.1038/leu.2014.222
  • Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Höglund, Martin; Koskenvesa, Perttu; Lotfi, Kourosh; Majeed, Mohammed Waleed; Markevärn, Berit; Ohm, Lotta; Olsson-Strömberg, Ulla; Remes, Kari; Suominen, Merja; Simonsson, Bengt; Porkka, Kimmo; Mustjoki, Satu; Richter, Johan. 2015. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). European Journal of Haematology. 94: 243-250. doi: 10.1111/ejh.12423
  • Landskron, Johannes; Helland, Øystein; Torgersen, Knut Martin; Aandahl, Einar Martin; Gjertsen, Bjørn Tore; Bjørge, Line; Tasken, Kjetil. 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 64: 337-347. doi: doi: 10.1007/s00262-014-1636-6
  • Landskron, Johannes; Helland, Øystein; Torgersen, Knut Martin; Aandahl, Einar Martin; Gjertsen, Bjørn Tore; Bjørge, Line; Tasken, Kjetil. 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 64: 337-347. Published 2014-11-22. doi: 10.1007/s00262-014-1636-6
  • Mukherjee, Herschel; Chan, Kok-Ping; Andresen, Vibeke; Hanley, Mariah L.; Gjertsen, Bjørn Tore; Myers, Andrew G. 2015. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. ACS Chemical Biology. 10: 855-863. doi: 10.1021/cb500872g
  • Myklebost, Ola; Lothe, Ragnhild A; Gjertsen, Bjørn Tore; Lønning, Per Eystein. 2015. Bør hver kreftpasient bli et eget forskningsprosjekt? Aftenposten (morgenutg. : trykt utg.). Published 2015-08-12.
  • Sandtorv, Alexander Harald; Leitch, Calum; Bedringaas, Siv Lise; Gjertsen, Bjørn Tore; Bjørsvik, Hans-Rene. 2015. 4-alkylated silver-N-heterocyclic carbene (NHC) complexes with cytotoxic effects in leukemia cells. ChemMedChem. 10: 1522-1527. doi: 10.1002/cmdc.201500234
  • Aasebø, Elise; Vaudel, Marc; Mjaavatten, Olav; Gausdal, Gro; van der Burgh, Arthur Edward Emiel; Gjertsen, Bjørn Tore; Doskeland, Stein Ove; Bruserud, Øystein; Berven, Frode; Selheim, Frode. 2014. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 14: 1971-1976. doi: 10.1002/pmic.201300448
  • Gavasso, Sonia; Mosleth, Ellen Færgestad; Marøy, Tove Helene; Jørgensen, Katarina Mariann; Nakkestad, Hanne Linda; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLoS ONE. 9. doi: 10.1371/journal.pone.0088632
  • Gjertsen, Bjørn Tore. 2014. Mot en mer spesifikk kreftbehandling? :. Tidsskrift for Den norske legeforening. 134: 1017. doi: 10.4045/tidsskr.14.0574
  • Haaland, Ingvild; Opsahl, Jill Anette; Berven, Frode; Reikvam, Håkon; Fredly, Hanne Kristin; Haugse, Ragnhild; Thiede, Bernd; McCormack, Emmet; Lain, Sonia; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer. 13. doi: 10.1186/1476-4598-13-116
  • Hampson, Peter; Wang, Keqing; Ersvær, Elisabeth; McCormack, Emmet; Schüler, Julia; Fiebig, Heinz-Herbert; Gjertsen, Bjørn Tore; Bruserud, Øystein; Lord, Janet M. 2014. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukemic compound PEP005 in primary AML cells. Oncoscience. 1: 529-539. doi: 10.18632/oncoscience.71
  • Helland, Øystein; Popa, Mihaela Lucia; Vintermyr, Olav Karsten; Molven, Anders; Gjertsen, Bjørn Tore; Bjørge, Line; McCormack, Emmet. 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS ONE. 9. doi: 10.1371/journal.pone.0089527
  • Kontro, M; Kuusanmäki, H; Eldfors, S; Burmeister, T; Andersson, EI; Gjertsen, Bjørn Tore. 2014. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 28: 1738-1742. doi: 10.1038/leu.2014.89
  • Kotopoulis, Spiros; Delalande, Anthony; Popa, Mihaela Lucia; Mamaeva, Veronika; Dimcevski, Georg Gjorgji; Gilja, Odd Helge; Postema, Michiel; Gjertsen, Bjørn Tore; McCormack, Emmet. 2014. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Molecular Imaging and Biology. 16: 53-62. doi: 10.1007/s11307-013-0672-5
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet; Postema, Michiel. 2014. Sonoporation: from the lab to human clinical trials. IEEE International Ultrasonics Symposium Proceedings. 846-849. doi: 10.1109/ULTSYM.2014.0208
  • Kotopoulis, Spiros; Haugse, Ragnhild; Mujic, Maja; Sulen, Andre; Gullaksen, Stein-Erik; McCormack, Emmet; Gilja, Odd Helge; Postema, Michiel; Gjertsen, Bjørn Tore. 2014. Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. IEEE International Ultrasonics Symposium Proceedings. 1186-1190. doi: 10.1109/ULTSYM.2014.0292
  • Li, Ling; Osdal, Tereza; Ho, Yinway; Chun, Sookhee; McDonald, Tinisha; Agarwal, Puneet; Lin, Allen; Chu, Su; Qi, Jing; Li, Liang; Hsieh, Yao-Te; Dos Santos, Cedric; Yuan, Hongfeng; Ha, Trung; Popa, Michaela; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore; Kuo, Ya-Huei; Chen, Wenyong; Lain, Sonia; McCormack, Emmet; Bhatia, Ravi. 2014. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 15: 431-446. doi: 10.1016/j.stem.2014.08.001
  • Rizzieri, David A.; Vey, Norbert; Thomas, Xavier; Huguet-Rigal, Françoise; Schlenk, Richard F.; Krauter, Jürgen; Kindler, Thomas; Gjertsen, Bjørn Tore; Blau, Igor Wolfgang; Jacobsen, Tove Flem; Johansen, Malin; Bergeland, Trygve; Gianella-Borradori, Athos; Krug, Utz. 2014. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma. 55: 2114-2119. doi: 10.3109/10428194.2013.867489
  • Andresen, Vibeke; Wang, Xiang; Ghimire, Sakhila; Omsland, Maria; Gjertsen, Bjørn Tore; Gerdes, Hans-Hermann. 2013. Tunneling nanotube (TNT) formation is independent of p53 expression. Cell Death and Differentiation. 20: 1124-1124. doi: 10.1038/cdd.2013.61
  • Bredholt, Therese; Ersvær, Elisabeth; Erikstein, Bjarte Skoe; Sulen, Andre; Reikvam, Håkon; Aarstad, Hans Jørgen; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 14. 13 pages. doi: 10.1186/2050-6511-14-35
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Kittang, Astrid Marta Olsnes; Tsykunova, Galina; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics. 5:13. doi: 10.1186/1868-7083-5-13
  • Fredly, Hanne Kristin; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics. 5:12. doi: 10.1186/1868-7083-5-12
  • Gausdal, Gro; Wergeland, Anita; Skavland, Jørn; Nguyen, Eric; Pendino, Frederic; ROUHEE, NAZANIN; McCormack, Emmet; Herfindal, Lars; Kleppe, Rune; Havemann, Ursula; Schwede, Frank; Bruserud, Øystein; Gjertsen, Bjørn Tore; Lanotte, Michel; Ségal-Bendirdjian, Evelyne; Doskeland, Stein Ove. 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease. 4. doi: 10.1038/cddis.2013.39
  • Helland, Øystein; Mihaela, P.; Gjertsen, Bjørn Tore; McCormack, Emmet; Bjørge, Line. 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 23. 1 pages.
  • Herfindal, Lars; Myhren, Lene Elisabeth; Gjertsen, Bjørn Tore; Doskeland, Stein Ove; Gausdal, Gro. 2013. Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer. 13. doi: 10.1186/1471-2407-13-341
  • Kloster, Martine Müller; Naderi, Elin Hallan; Haaland, Ingvild; Gjertsen, Bjørn Tore; Blomhoff, Heidi Kiil; Naderi, Soheil. 2013. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. International Journal of Oncology. 42: 1815-1821. doi: 10.3892/ijo.2013.1853
  • McCormack, Emmet; Adams, Katherine J.; Hassan, Namir J.; Kotian, Akhil; Lissin, Nikolai M.; Sami, Malkit; Mujic, Maja; Osdal, Tereza; Gjertsen, Bjørn Tore; Baker, Deborah; Powlesland, Alex S.; Aleksic, Milos; Vuidepot, Annelise; Morteau, Oliver; Sutton, Deborah H.; June, Carl H.; Kalos, Michael; Ashfield, Rebecca; Jakobsen, Bent K. 2013. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunology and Immunotherapy. 62: 773-785. doi: 10.1007/s00262-012-1384-4
  • McCormack, Emmet; Mujic, Maja; Osdal, Tereza; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2013. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 121: E34-E42. doi: 10.1182/blood-2012-05-429555
  • McCormack, Emmet; Silden, Elisabeth; West, Richard M.; Pavlin, Tina; Micklem, David Robert; Lorens, James; Haug, Bengt Erik; Cooper, Michael E.; Gjertsen, Bjørn Tore. 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 74: 1276-1286. doi: 10.1158/0008-5472.CAN-12-2649
  • Mustjoki, Satu; Richter, Johan; Barbany, Gisela; Ehrencrona, Hans; Fioretos, Thoas; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Hovland, Randi; Hernesniemi, Sari; Josefsen, Dag; Koskenvesa, Perttu; Dybedal, Ingunn; Markevärn, Berit; Olofsson, Tor; Olsson-Strömberg, Ulla; Rapakko, Katrin; Thunberg, Sarah; Stenke, Leif; Simonsson, Bengt; Porkka, Kimmo; Hjort-Hansen, Henrik. 2013. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 27: 1520-1526. doi: 10.1038/leu.2013.19
  • Pemovska, Tea; Kontro, Mika; Yadav, Bhagwan; Edgren, Henrik; Eldfors, Samuli; Szwajda, Agnieszka; Almusa, Henrikki; Bespalov, Maxim M.; Ellonen, Pekka; Elonen, Erkki; Gjertsen, Bjørn Tore; Karjalainen, Riikka; Kulesskiy, Evgeny; Lagström, Sonja; Lehto, Anna; Lepistö, Maija; Lundan, Tuija; Majumder, Muntasir Mamun; Marti, Jesus M. Lopez; Mattila, Pirkko; Murumagi, Astrid; Mustjoki, Satu; Palva, Aino; Parsons, Alun; Pirttinen, Tero; Rämet, Maria E.; Suvela, Minna; Turunen, Laura; Västrik, Imre; Wolf, Maija; Knowles, Jonathan; Aittokallio, Tero; Heckman, Caroline A.; Porkka, Kimmo; Kallioniemi, Olli; Wennerberg, Krister. 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery. 3: 1416-1429. doi: 10.1158/2159-8290.CD-13-0350
  • Reikvam, Håkon; Kittang, Astrid Marta Olsnes; Melve, Guro Kristin; Mosevoll, Knut Anders; Bentsen, Pål Tore; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 13: 30-47. doi: 10.2174/1568009611309010030
  • Reikvam, Håkon; Nepstad, Ina; Sulen, Andre; Gjertsen, Bjørn Tore; Hatfield, Kimberley Joanne; Bruserud, Øystein. 2013. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 22: 551-563. doi: 10.1517/13543784.2013.791280
  • Silden, Elisabeth; Hjelle, Sigrun Margrethe; Wergeland, Line; Sulen, Andre; Andresen, Vibeke; Bourdon, Jean-Christophe; Micklem, David Robert; McCormack, Emmet; Gjertsen, Bjørn Tore. 2013. Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. PLoS ONE. 8. 11 pages. doi: 10.1371/journal.pone.0056276
  • Øye, Ola Kristoffer; Jørgensen, Katarina Mariann; Hjelle, Sigrun Margrethe; Sulen, Andre; Ulvang, Dag Magne; Gjertsen, Bjørn Tore. 2013. Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. BMC Bioinformatics. 14. 5 pages. doi: 10.1186/1471-2105-14-215
  • Bjugn, Roger; Gjertsen, Bjørn Tore. 2012. Humane celler og helseforskningsloven. Tidsskrift for Den norske legeforening. 132: 540-542. doi: 10.4045/tidsskr.11.1076
  • Forthun, Rakel Brendsdal; Sengupta, Tanima; Skjeldam, Hanne Kim; Lindvall, Jessica Margareta; Mccormack, Emmet Martin; Gjertsen, Bjørn Tore; Nilsen, Hilde. 2012. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS ONE. 7. doi: 10.1371/journal.pone.0048992
  • Fredly, Hanne Kristin; Reikvam, Håkon; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 87: 368-376. doi: 10.1002/ajh.23116
  • Gavasso, Sonia; Gjertsen, Bjørn Tore; Anderssen, Endre; Myhr, Kjell-Morten; Vedeler, Christian A. 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 18: 1116-1124. doi: 10.1177/1352458511434066
  • Gavasso, Sonia; Marøy, Tove Helene; Mosleth, Ellen Færgestad; Jørgensen, Katarina Mariann; Nakkestad, Hanne Linda; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 253: 18-19.
  • Giles, Francis; Mahon, François-Xavier; Gjertsen, Bjørn Tore; Swords, Roman; Labar, Boris; Turkina, Anna; Rosti, Gianantonio. 2012. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation. 42: 1016-1026. doi: 10.1111/j.1365-2362.2012.02675.x
  • Gjertsen, Bjørn Tore; Wiig, Helge. 2012. Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. Espert Review of Proteomics. 9: 595-598. doi: 10.1586/EPR.12.55
  • Hallenborg, Philip; Feddersen, Søren; Francoz, Sarah; Murano, Incoronata; Sundekilde, Ulrik; Petersen, R.K.; Akimov, Vyacheslav; Olson, M.V.; Lozano, Guillermina; Cinti, Saverio; Gjertsen, Bjørn Tore; Madsen, Lise; Marine, Jean-Christophe; Blagoev, Blagoy; Kristiansen, Karsten. 2012. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death and Differentiation. 19: 1381-1389. doi: 10.1038/cdd.2012.15
  • Helland, Øystein; Popa, Mihaela Lucia; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore; Bjørge, Line; Mccormack, Emmet Martin. 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 91: 16-17.
  • Hjelle, Sigrun Margrethe; Sulen, Andre; Øye, Ola Kristoffer; Jørgensen, Katarina Mariann; McCormack, Emmet Martin; Hollund, Eli Bjørg; Gjertsen, Bjørn Tore. 2012. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. Journal of Proteomics. 76: 69-78. doi: 10.1016/j.jprot.2012.07.021
  • McCormack, Emmet Martin; Haaland, Ingvild; Venås, Gurid; Forthun, Rakel Brendsdal; Huseby, Sjur; Gausdal, Gro; Knappskog, Stian; Micklem, David Robert; Lorens, James; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 26: 910-917. doi: 10.1038/leu.2011.315
  • Oveland, Eystein; Wergeland, Line; Hovland, Randi; Lorens, James; Gjertsen, Bjørn Tore; Fladmark, Kari Espolin. 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 28: 201-212. doi: 10.1007/s10565-012-9216-z
  • Reikvam, Håkon; Hatfield, Kimberley Joanne; Ersvær, Elisabeth; Hovland, Randi; Skavland, Jørn; Gjertsen, Bjørn Tore; Petersen, Kjell; Bruserud, Øystein. 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 156: 468-480. doi: 10.1111/j.1365-2141.2011.08960.x
  • Rizzieri, David A.; Vey, Norbert; Thomas, Xavier; Huguet, Francoise; Schlenk, Richard F; Krauter, Jürgen; Kindler, Thomas; Gjertsen, Bjørn Tore; Blau, Igor W.; Johansen, Malin; Bergeland, Trygve; Gianella-Borradori, Athos; Jacobsen, Tove Flem; Rao, Jianyu; Krug, Utz. 2012. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood. 120. 2 pages.
  • Tsykunova, Galina; Reikvam, Håkon; Ahmed, Aymen B; Nepstad, Ina; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2012. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 21: 587-603. doi: 10.1517/13543784.2012.668525
  • Ånensen, Nina; Hjelle, Sigrun Margrethe; Van, Belle Werner; Haaland, Ingvild; Silden, Elisabeth; Bourdon, Jean-Christophe; Hovland, Randi; Tasken, Kjetil; Knappskog, Stian; Lønning, Per Eystein; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 31: 1533-1545. doi: 10.1038/onc.2011.348
  • Øye, Ola Kristoffer; Ulvang, Dag Magne; Jørgensen, Katarina Mariann; Hjelle, Sigrun Margrethe; Gjertsen, Bjørn Tore. 2012. Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. Computer-Based Medical Systems. 1-6. Published 2012-08-30. doi: 10.1109/CBMS.2012.6266326
  • Fredly, Hanne Kristin; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 25: 1549-1556. doi: 10.3892/or.2011.1229
  • Gjertsen, Bjørn Tore. 2011. Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. Expert Review of Anticancer Therapy. 11: 355-357. doi: 10.1586/ERA.11.8
  • Jørgensen, Katarina Mariann; Hjelle, Sigrun Margrethe; Øye, Ola Kristoffer; Puntervoll, Pål; Reikvam, Håkon; Skavland, Jørn; Anderssen, Endre; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 74: 269-281. doi: 10.1016/j.jprot.2010.11.003
  • Skavland, Jørn; Jørgensen, Katarina Mariann; Hadziavdic, Kenan; Hovland, Randi; Jonassen, Inge; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal. 1. doi: 10.1038/bcj.2011.2
  • Tiron, Crina Elena; Gjerdrum, Christine; Høiby, Torill; Maugen, Hallvard; Stefansson, Ingunn Marie; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet Martin; Gjertsen, Bjørn Tore; Micklem, David Robert; Akslen, Lars A.; Glackin, Carlotta A.; Lorens, James. 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 28: 234-235.
  • Erikstein, Bjarte Skoe; Hagland, Hanne; Nikolaisen, Julie; Kulawiec, Marion; Singh, Keshav K.; Gjertsen, Bjørn Tore; Tronstad, Karl Johan. 2010. Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. Journal of Cellular Biochemistry. 111: 574-584. doi: 10.1002/jcb.22741
  • Erikstein, Bjarte Skoe; McCormack, Emmet Martin; Tronstad, Karl Johan; Schwede, Frank; Berge, Rolf Kristian; Gjertsen, Bjørn Tore. 2010. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 34: 77-84. doi: 10.1016/j.leukres.2009.09.005
  • Ersvær, Elisabeth; Liseth, Knut; Skavland, Jørn; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology. 11. doi: 10.1186/1471-2172-11-38
  • Fredly, Hanne Kristin; Bjørnsen, Camilla I. Stapnes; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 15: 338-343. doi: 10.1179/102453310X12647083620967
  • Gjerdrum, Christine; Tiron, Crina Elena; Høiby, Torill; Stefansson, Ingunn Marie; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet Martin; Gjertsen, Bjørn Tore; Micklem, David Robert; Akslen, Lars A.; Glackin, Carlotta A.; Lorens, James. 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 107: 1124-1129. doi: 10.1073/pnas.0909333107
  • Hatfield, Kimberley Joanne; Bedringaas, Siv Lise; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. 38: S119-S119.
  • Hatfield, Kimberley Joanne; Bedringaas, Siv Lise; Ryningen, Anita; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 21: 154-164. doi: 10.1684/ecn.2010.0204
  • Hjelle, Sigrun Margrethe; Forthun, Rakel Brendsdal; Haaland, Ingvild; Reikvam, Håkon; Sjøholt, Gry; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2010. Clinical proteomics of myeloid leukemia. Genomu Igaku : Genome Medicine. 2. doi: 10.1186/gm162
  • McCormack, Emmet Martin; Skavland, Jørn; Mujic, Maja; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 62: 574-583. doi: 10.1080/01635580903532416
  • Semaeva, Elvira; Tenstad, Olav; Skavland, Jørn; Enger, Marianne; Iversen, Per Ole; Gjertsen, Bjørn Tore; Wiig, Helge. 2010. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 184: 4547-4556. doi: 10.4049/jimmunol.0902049
  • Skavland, Jørn; Hadziavdic, Kenan; Jonassen, Inge; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 95: 510-510.
  • Bredholt, Therese; Dimba, Elisabeth Anne Okumu; Hagland, Hanne; Wergeland, Line; Skavland, Jørn; Fossan, Kjell O.; Tronstad, Karl Johan; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore. 2009. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer. 8. doi: 10.1186/1476-4598-8-101
  • Christoffersen, Thoralf; Guren, Tormod K.; Spindler, Karen-Lise Garm; Dahl, Olav; Lønning, Per Eystein; Gjertsen, Bjørn Tore. 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 625: 6-22. doi: 10.1016/j.ejphar.2009.10.009
  • Gjertsen, Bjørn Tore. 2009. Er høyt hemoglobinnivå farlig? Tidsskrift for Den norske legeforening. 129: 1881-1882. doi: 10.4045/tidsskr.09.0995
  • Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Ersvær, Elisabeth; Kalland, Karl-Henning; Lassalle, Philippe; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
  • Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Ersvær, Elisabeth; Kalland, Karl-Henning; Lassalle, Philippe; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 144: 53-68. doi: 10.1111/j.1365-2141.2008.07411.x
  • Hofmann, Matthias; McCormack, Emmet Martin; Mujic, Maja; Roßberg, Maila; Bernd, August; Bereiter-Hahn, Jürgen; Gjertsen, Bjørn Tore; Wiig, Helge; Kippenberger, Stefan. 2009. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model. Neoplasia. 11: 812-822.
  • Lukandu, Ochiba Mohammed; Bredholt, Therese; Neppelberg, Evelyn; Gjertsen, Bjørn Tore; Johannessen, Anne Chr.; Vintermyr, Olav Karsten; Costea, Daniela Elena. 2009. Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. Toxicology. 263: 108-116. doi: 10.1016/j.tox.2009.06.024
  • Olsnes, Astrid Marta; Ersvær, Elisabeth; Ryningen, Anita; Paulsen, Kristin; Hampson, Peter; Lord, Janet M.; Gjertsen, Bjørn Tore; Kristoffersen, Einar Klæboe; Bruserud, Øystein. 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 145: 761-774. doi: 10.1111/j.1365-2141.2009.07691.x
  • Oveland, Eystein; Gjertsen, Bjørn Tore; Wergeland, Line; Selheim, Frode; Fladmark, Kari Espolin; Hovland, Randi. 2009. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 33: 276-287. doi: 10.1016/j.leukres.2008.06.029
  • Reikvam, Håkon; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore; Ersvær, Elisabeth; Bruserud, Øystein. 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 15: 1-41.
  • Ryningen, Anita; Stapnes, Camilla I; Lassalle, Philippe; Corbascio, Matthias A; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2009. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 33: 779-787. doi: 10.1016/j.leukres.2008.10.005
  • Stapnes, Camilla I; Gjertsen, Bjørn Tore; Reikvam, Håkon; Bruserud, Øystein. 2009. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 18: 433-455. doi: 10.1517/14728220902787628
  • Wang, Jian; Tsinkalovsky, Oleg; Zhao, P; Prestegarden, L; Li, X; Cormark, E; Gjertsen, Bjørn Tore; Bjerkvig, Rolf; Enger, Per Øyvind. 2009. TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. Neuro-Oncology. 11: 965-965.
  • Øyan, Anne Margrete; Ånensen, Nina; Bø, Trond Hellem; Stordrange, Laila; Jonassen, Inge; Bruserud, Øystein; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer. 9. doi: 10.1186/1471-2407-9-77
  • Bruserud, Øystein; Ersvær, Elisabeth; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore. 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 8: 666-675. doi: 10.2174/156800908786733496
  • Gausdal, Gro; Gjertsen, Bjørn Tore; McCormack, Emmet Martin; Van Damme, Petra; Hovland, Randi; Krakstad, Camilla; Bruserud, Øystein; Gevaert, Kris; Vandekerckhove, Joel; Doskeland, Stein Ove. 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 111: 2866-2877. doi: 10.1182/blood-2007-07-103242
  • Gavasso, Sonia; Skavland, Jørn; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Vedeler, Christian A. 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 203: 134-135.
  • Gjertsen, Bjørn Tore; McCormack, Emmet Martin. 2008. Erythropoietin a safe bet in haemorrhagic shock? Acta Anaesthesiologica Scandinavica. 52: 585-586. doi: 10.1111/j.1399-6576.2008.01651.x
  • Hatfield, Kimberley Joanne; Hovland, Randi; Øyan, Anne Margrete; Kalland, Karl-Henning; Ryningen, Anita; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 22: 287-293. doi: 10.1038/sj.leu.2404985
  • Kirkeleit, Jorunn; Riise, Trond; Gjertsen, Bjørn Tore; Moen, Bente Elisabeth; Bråtveit, Magne; Bruserud, Øystein. 2008. Effects of benzene on human hematopoiesis. The Open Hematology Journal. 2: 87-102. doi: 10.2174/1874276900802010087
  • Lukandu, Ochiba Mohammed; Costea, Daniela Elena; Dimba, Elisabeth Anne Okumu; Neppelberg, Evelyn; Bredholt, Therese; Gjertsen, Bjørn Tore; Vintermyr, Olav; Johannessen, Anne Chr. 2008. Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences. 116: 23-30. doi: 10.1111/j.1600-0722.2007.00508.x
  • McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2008. Review: genetic models of acute myeloid leukaemia. Oncogene. 27: 3765-3779. doi: 10.1038/onc.2008.16
  • McCormack, Emmet Martin; Haaland, Ingvild; Venås, Gurid; Forthun, Rakel Brendsdal; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2008. Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 112: 1024-1024.
  • Ryningen, Anita; Stapnes, Camilla I; Paulsen, Kristin; Lassall, Philippe; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2008. In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 17: 1623-1633. doi: 10.1517/13543780802440136
  • Wergeland, Line; Oveland, Eystein; Sjøholt, Gry; Bedringaas, Siv Lise; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 93: 10-10.
  • Bruserud, Øystein; Ryningen, Anita; Olsnes, Astrid Marta; Stordrange, Laila; Øyan, Anne Margrete; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 92: 332-341.
  • Bruserud, Øystein; Stapnes, Camilla I; Ersvær, Elisabeth; Gjertsen, Bjørn Tore; Ryningen, Anita. 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 8: 388-400. doi: 10.2174/138920107783018417
  • Erikstein, Bjarte Skoe; Tronstad, Karl Johan; McCormack, Emmet Martin; Schwede, Frank; Berge, Rolf Kristian; Gjertsen, Bjørn Tore. 2007. Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. Blood. 110: 117B-117B.
  • Ersvær, Elisabeth; Hampson, Peter; Hatfield, Kimberley Joanne; Ulvestad, Elling; Wendelbo, Øystein; Lord, Janet M.; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 56: 013-925. doi: 10.1007/s00262-006-0236-5
  • Ersvær, Elisabeth; Hampson, Peter; Wendelbo, Øystein; Lord, Janet M.; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 12: 199-207. doi: 10.1080/10245330701255163
  • Ersvær, Elisabeth; Skavland, Jørn; Ulvestad, Elling; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 56: 13-24. doi: 10.1007/s00262-006-0159-1
  • Ersvær, Elisabeth; Zhang, Jian-Ying; McCormack, Emmet Martin; Olsnes, Astrid Marta; Ånensen, Nina; Tan, Eng M.; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 79: 210-225. doi: 10.1111/j.1600-0609.2007.00899.x
  • Gjertsen, Bjørn Tore; Bredholt, Therese; Ånensen, Nina; Vintermyr, Olav. 2007. Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. Current Pharmaceutical Biotechnology. 8: 373-381. doi: 10.2174/138920107783018381
  • Hagland, Hanne; Nikolaisen, Julie; Hodneland, Linn Iren; Gjertsen, Bjørn Tore; Bruserud, Øystein; Tronstad, Karl Johan. 2007. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert opinion on therapeutic targets. 11: 1055-1069. doi: 10.1517/14728222.11.8.1055
  • Huang, Tien-Sheng; Myklebust, Line Merethe; Kjærland, Endre; Gjertsen, Bjørn Tore; Pendino, Frederic; Bruserud, Øystein; Doskeland, Stein Ove; Lillehaug, Johan. 2007. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer. 6. doi: 10.1186/1476-4598-6-31
  • Irish, Jonathan C.; Ånensen, Nina; Hovland, Randi; Skavland, Jørn; Børresen-Dale, Anne-Lise; Bruserud, Øystein; Nolan, Gary P; Gjertsen, Bjørn Tore. 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 109: 2589-2596. doi: 10.1182/blood-2006-02-004234
  • McCormack, Emmet Martin; Belankov, Alexandre; Mujic, Maja; Couture, Pierre; Gjertsen, Bjørn Tore. 2007. Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. Blood. 110: 147B-148B.
  • McCormack, Emmet Martin; Micklem, David Robert; Pindard, Lars Erik; Silden, Elisabeth; Gallant, Pascal; Belenkov, Alexandre; Lorens, James; Gjertsen, Bjørn Tore. 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 6: 193-204. doi: 10.2310/7290.2007.00016
  • Parlati, Francesco; Aujay, Monette; Bedringaas, Siv Lise; Demo, Susan; Gjertsen, Bjørn Tore; Goldstein, Eileen; Jiang, Jing; Kirk, Christopher; Laidig, Guy; Lorens, James; Lu, Yan; Micklem, David Robert; Ruurs, Paulina; Shenk, Kevin; Sylvain, Catherine; Sun, Congcong; Woo, Tina; Zhou, Han-Jie; Bennett, Mark. 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 110: 477A-478A.
  • Petersen, Kjell; Øyan, Anne Margrete; Rostad, Kari; Olsen, Sue; Bø, Trond Hellem; Salvesen, Helga; Gjertsen, Bjørn Tore; Bruserud, Øystein; Halvorsen, Ole Johan; Akslen, Lars A.; Steen, Vidar Martin; Jonassen, Inge; Kalland, Karl-Henning. 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 366: 46-58. doi: 10.1016/j.ab.2007.03.013
  • Stapnes, Camilla I; Døskeland, Anne Paulus; Hatfield, Kimberley Joanne; Ersvær, Elisabeth; Ryningen, Anita; Lorens, James; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 136: 814-828. doi: 10.1111/j.1365-2141.2007.06504.x
  • Stapnes, Camilla I; Ryningen, Anita; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Eide, Geir Egil; Corbascio, Matthias; Kalland, Karl-Henning; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 31: 1529-1538.
  • Stapnes, Camilla I; Ryningen, Anita; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Eide, Geir Egil; Kalland, Karl-Henning; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 92: 112-112.
  • Stapnes, Camilla I; Ryningen, Anita; Hatfield, Kimberley Joanne; Øyan, Anne Margrete; Kalland, Karl-Henning; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 35: 77-77.
  • Wergeland, Line; Oveland, Eystein; Sjøholt, Gry; Bedringaas, Siv Lise; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 110: 148B-148B.
  • Wergeland, Line; Sjøholt, Gry; Haaland, Ingvild; Hovland, Randi; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2007. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer. 6. doi: 10.1186/1476-4598-6-33
  • Ånensen, Nina; Øyan, Anne Margrete; Huseby, Sjur; Kalland, Karl-Henning; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 7: 741-751. doi: 10.1586/14737140.7.5.741
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Ulvestad, Elling; Gjertsen, Bjørn Tore; Bruserud, Øystein; Kalland, Karl-Henning. 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 8: 344-354. doi: 10.2174/138920107783018435
  • Belle, Werner Van; Ånensen, Nina; Haaland, Ingvild; Bruserud, Øystein; Høgda, Kjell-Arild; Gjertsen, Bjørn Tore. 2006. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 7: 198. doi: 10.1186/1471-2105-7-198
  • Bruserud, Øystein; McCormack, Emmet Martin; Gjertsen, Bjørn Tore. 2006. Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology and Immunotherapy. 55: 185-187. doi: 10.1007/s00262-005-0031-8
  • Bruserud, Øystein; Stapnes, Camilla I; Tronstad, Karl Johan; Ryningen, Anita; Ånensen, Nina; Gjertsen, Bjørn Tore. 2006. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert opinion on therapeutic targets. 10: 51-68. doi: 10.1517/14728222.10.1.51
  • Bruserud, Øystein; Tronstad, Karl Johan; McCormack, Emmet Martin; Gjertsen, Bjørn Tore. 2006. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 55: 221-228. doi: 10.1007/s00262-005-0032-7
  • Krakstad, Camilla; Herfindal, Lars; Gjertsen, Bjørn Tore; Bøe, Roald; Vintermyr, Olav Karsten; Fladmark, Kari Espolin; Doskeland, Stein Ove. 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 13: 1191-1202. doi: 10.1038/sj.cdd.4401798
  • Oveland, Eystein; Fladmark, Kari Espolin; Wergeland, Line; Gjertsen, Bjørn Tore; Hovland, Randi. 2006. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. Current Pharmaceutical Biotechnology. 7: 185-198. doi: 10.2174/138920106777549696
  • Ryningen, Anita; Ersvær, Elisabeth; Øyan, Anne Margrete; Kalland, Karl-Henning; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 30: 1531-1540.
  • Sjøholt, Gry; Bedringaas, Siv Lise; Døskeland, Anne Paulus; Gjertsen, Bjørn Tore. 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 7: 159-170. doi: 10.2174/138920106777549759
  • Sjøholt, Gry; Bedringaas, Siv Lise; Døskeland, Anne Paulus; Gjertsen, Bjørn Tore. 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 7: 159-170. doi: 10.2174/138920106777549759
  • Stapnes, Camilla I; Ryningen, Anita; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2006. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncologica. 45: 346-349. doi: 10.1080/02841860500482233
  • Van Belle, Werner; Sjøholt, Gry; Ånensen, Nina; Høgda, Kjell-Arild; Gjertsen, Bjørn Tore. 2006. Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. Electrophoresis. 27: 4086-4095. doi: 10.1002/elps.200500925
  • Ånensen, Nina; Haaland, Ingvild; D Santos, Clive; Belle, Werner Van; Gjertsen, Bjørn Tore. 2006. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Current Pharmaceutical Biotechnology. 7: 199-207. doi: 10.2174/138920106777549731
  • Ånensen, Nina; Skavland, Jørn; Stapnes, Camilla I; Ryningen, Anita; Børresen-Dale, Anne-Lise; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2006. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia. 20: 734-736. doi: 10.1038/sj.leu.2404117
  • Ånensen, Nina; Øyan, Anne Margrete; Bourdon, Jean-Christophe; Kalland, Karl-Henning; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 12: 3985-3992. doi: 10.1158/1078-0432.CCR-05-1970
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Gjertsen, Bjørn Tore; Bruserud, Øystein; Kalland, Karl-Henning. 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 1: 106.
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Gjertsen, Bjørn Tore; Bruserud, Øystein; Kalland, Karl-Henning. 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 28: 1065-1080.
  • Øyan, Anne Margrete; Ånensen, Nina; Bø, Trond Hellem; Stordrange, Laila; Jonassen, Inge; Bruserud, Øystein; Kalland, Karl-Henning; Gjertsen, Bjørn Tore. 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. 18: S65. Published 2006-10-13.
  • Bredholt, Therese; Dimba, Elisabeth Anne Okumu; Johannessen, Anne Chr.; Costea, Daniela-Elena; Francis, George W; Vintermyr, Olav Karsten; Gjertsen, Bjørn Tore. 2005. The role of Bcl-2 in apoptosis induced by khat (Catha edulis) in acute myeloid leukemia cell lines. Blood. 106: 195b-195b.
  • Hatfield, Kimberley Joanne; Olsnes, Astrid Marta; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 5: 229-248.
  • McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2005. Animal models of acute myelogenous leukaemia - development, application and future perspectives. Leukemia. 19: 687-706. doi: 10.1038/sj.leu.2403670
  • Ryningen, Anita; Wergeland, Line; Glenjen, Nils; Gjertsen, Bjørn Tore; Bruserud, Øystein. 2005. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis. 29: 185-196. doi: 10.1016/j.leukres.2004.06.008
  • Sjøholt, Gry; Ånensen, Nina; Wergeland, Line; McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2005. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 6: 631-646. doi: 10.2174/1389450054863671
  • Sjøholt, Gry; Ånensen, Nina; Wergeland, Line; McCormack, Emmet Martin; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2005. Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 6: 631-646. doi: 10.2174/1389450054863671
  • Øyan, Anne Margrete; Bø, Trond Hellem; Jonassen, Inge; Ulvestad, Elling; Gjertsen, Bjørn Tore; Kalland, Karl-Henning; Bruserud, Øystein. 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 64B: 18-27. doi: 10.1002/cyto.b.20044
  • Berentsen, Sigbjørn; Ulvestad, Elling; Gjertsen, Bjørn Tore; Hjorth-Hansen, H.; Langholm, R.; Knutsen, H.; Ghanima, W.; Shammas, Fuad Victor; Tjønnfjord, G.E. 2004. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 103: 2925-2928.
  • Berentsen, Sigbjørn; Ulvestad, Elling; Gjertsen, Bjørn Tore; Hjorth-Hansen, Henrik; Langholm, Ruth; Knutsen, Håvar; Ghanima, Waleed; Shammas, Fuad Victor; Tjønnfjord, Geir E. 2004. Rituximab for pimary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 103: 2925-2928. doi: 10.1182/blood-2003-10-3597
  • Bruserud, Øystein; Ryningen, Anita; Wergeland, Line; Glenjen, Nils; Gjertsen, Bjørn Tore. 2004. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 89: 391-402.
  • Dimba, E.A.; Gjertsen, Bjørn Tore; Bredholt, Therese; Fossan, K.O.; Costea, Daniela-Elena; Francis, George W; Johannessen, Anne Chr.; Vintermyr, Olav Karsten. 2004. Khat (Catha edulis)-induced apoptosis is inhibited by antagonists of caspase-1 and -8 in human leukaemia cells. British Journal of Cancer. 91: 1726-1726.
  • Ersvær, Elisabeth; Bertelsen, Liv-Turid; Espenes, Lars Christian; Bredholt, Therese; Bøe, Stig Ove; Iversen, Bjarne Magnus; Bruserud, Øystein; Ulvestad, Elling; Gjertsen, Bjørn Tore. 2004. Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease. Scandinavian Journal of Immunology. 60: 189-198. doi: 10.1111/j.0300-9475.2004.01450.x
  • Gausdal, Gro; Gjertsen, Bjørn Tore; Fladmark, Kari Espolin; Demol, H.; Vandekerckhove, Joel; Døskeland, Stein Ove. 2004. Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis. Leukemia. 18: 1989-1996.
  • Gjertsen, Bjørn Tore; Bruserud, Øystein. 2004. How should clinical data be included in experimental studies of cancer immunology? Cancer Immunology and Immunotherapy. 53: 677-680.
  • Irish, J.M.; Hovland, R.; Krutzik, P.O.; Perez, O.D.; Bruserud, Øystein; Gjertsen, Bjørn Tore; Nolan, G.P. 2004. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 118: 217-228.
  • Cimpan, Mihaela Roxana; Muna, Ziad Ahmed; Sørnes, Steinar; Gjertsen, Bjørn Tore; Matre, Roald; Skaug, Nils. 2001. Vitamin E prevents apoptosis and necrosis in U-937 cells exposed to eluates from autopolymerized denture base acrylic resins. Journal of Dental Research. 80: 1291-1291.
  • Bruserud, Øystein; Gjertsen, Bjørn Tore; von Volkman, Hilde L. 2000. In vitro Culture of Human Acute Myelogenous Leukemia (AML) Cells in Serum-Free Media: Studies of Native AML Blasts and AML Cell Lines. Journal of Hematotherapy & Stem Cell Research. 9: 923-932.
  • Cimpan, Mihaela Roxana; Cressey, Lill Irene; Skaug, Nils; Halstensen, Alfred; Lie, Stein Atle; Gjertsen, Bjørn Tore; Matre, Roald. 2000. Patterns of cell death induced by eluates from denture base acrylic resins in U-937 human monoblastoid cells. European Journal of Oral Sciences. 108: 59-69.
  • Cimpan, Mihaela Roxana; Skaug, Nils; Gjertsen, Bjørn Tore; Matre, Roald. 1999. Altered clonogenicity and induction of apoptotic cell death in L929 cells exposed to denture base acrylic resins. Journal of Dental Research. 78: 315-315.
  • Fladmark, Kari Espolin; Brustugun, Odd Terje; Hovland, Randi; Bøe, Ragnar; Gjertsen, Bjørn Tore; Zhivotovsky, B; Døskeland, Stein Ove. 1999. Ultrarapid apoptosis inducted by phosphatase inhibitors. Cell Death Differ. Cell Death and Differentiation. 6: 1099-1108.
  • Jensen, PH; Fladmark, Kari Espolin; Gjertsen, Bjørn Tore; Vintermyr, Olav Karsten. 1999. Caspase I related protease inhibition retards the execution of okadaic acid and camptothecin induced apoptosis and PAI-2 selective cleavage, but not commitment to cell death in HL-60 cells. British Journal of Cancer. 79: 1685-1691.
  • Austad, Joar; Bjerke, Jens Roar; Gjertsen, Bjørn Tore; Helland, Svein; Livden, John Karsten; Morken, Tore; Mørk, Nils-Jørgen. 1998. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology. 11: 19-24.
  • Cimpan, Mihaela Roxana; Gjertsen, Bjørn Tore; Skaug, Nils; Gjerdet, Nils Roar; Heggø Hansen, Bente; Matre, Roald. 1998. A comparative study of cytopathogenic effects of four denture base acrylic resins. Journal of Dental Research. 77: 816-816.
  • Fladmark, Kari Espolin; Gjertsen, Bjørn Tore; Døskeland, Stein Ove; Vintermyr, Olav Karsten. 1997. Fas/APO-1 (CD95)-Induced Apoptosis of Primary Hepatocytes Is Inhibited by cAMP. Biochemical and Biophysical Research Communications - BBRC. 232: 20-25.
  • Fladmark, Kari Espolin; Gjertsen, Bjørn Tore; Molven, Anders; Mellgren, Gunnar; Vintermyr, Olav Karsten; Døskeland, Stein Ove. 1997. Gap junctions and growth control in liver regeneration and in isolated rat hepatocytes. Hepatology. 25: 847-855.
  • Gjertsen, Bjørn Tore. 1996. Kreftcellens skjulte veier til apotose. KreftNytt. 4. nove.
  • Gjertsen, Bjørn Tore; Cressey, L. I.; Ruchaud, S.; Houge, G.; Lanotte, M.; Døskeland, Stein Ove. 1994. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. Journal of Cell Science, Supplement. 107: 3363-3377.
  • Jensen, P. H.; Cressey, L.; Gjertsen, Bjørn Tore; Madsen, P.; Mellgren, Gunnar; Hokland, P.; Gliemann, J.; Døskeland, Stein Ove; Lanotte, M.; Vintermyr, Olav Karsten. 1994. Cleaved intracellular plasminogen activator inhibitor-2 is a marker of apoptosis present in human myeloid leukemia cells. British Journal of Cancer. 70: 834-840.
  • Døskeland, Stein Ove; Maronde, E.; Gjertsen, Bjørn Tore. 1993. The genetic subtypes of cAMP-dependent protein kinase - functionally different or redundant? Biochimica et Biophysica Acta. 1178: 249-258.
  • Gjertsen, Bjørn Tore; Duprez, E.; Bernard, O.; Lanotte, M.; Døskeland, Stein Ove. 1993. Anti-apoptotic effect of heterozygously expressed mutant RI (Ala%3%3%6 ->Asp) subunit of cAMP-kinase I in a rat leukaemia cell line. Journal of Biological Chemistry. 268: 8332-8340.
  • Gjertsen, Bjørn Tore; Fauske, B.; Døskeland, Stein Ove. 1993. Exogenous substrate stimulate autodephosphorylation of cyclic-AMP-dependent protein kinase II. Biochemical Journal. 294: 497-503.
  • Houge, G.; Cressey, L. I.; Gjertsen, Bjørn Tore. 1993. Apoptosisk celledød - finnes det fornuft i fragmenteringen? NBS-nytt. 4: 6-12.
  • Houge, G.; Døskeland, Stein Ove; Gjertsen, Bjørn Tore. 1993. Apoptotisk celledød. NBS-nytt. 4: 6-12.
Reports and theses
  • Gjertsen, Bjørn Tore. 1995. cAMP-dependent protein kinase: Its regulation and its role in apoptosis of a promyelocytic leukemia cell line.
Book sections
  • Kotopoulis, Spiros; Popa, Mihaela Lucia; Safont, MJ; Stigen, Endre; Healey, Andrew; Kvåle, Svein; Sontum, Per Chrisian; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2015. Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume. KAPITTEL, pages 119-119. In:
    • Nortvedt, Ragnar; Haldorsen, Ingfrid S.; Gilja, Odd Helge. 2015. Innovation in Imaging & Vizualization. The MedViz Conference 2015. Allkopi Forlag. 173 pages. ISBN: 978-82-998920-5-6.
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Hoem, Dag; Postema, Michiel; Gjertsen, Bjørn Tore; Bjånes, Tormod Karlsen; Biermann, Martin; Mccormack, Emmet Martin; Sorbye, Halfdan; Molven, Anders; Gilja, Odd Helge. 2013. Ultrasound-assisted treatment of an inoperable pancreatic cancer. Session 2, pages 49-52. In:
    • Nortvedt, Ragnar; Gilja, Odd Helge. 2013. MedViz Conference 2013. 146 pages. ISBN: 978-82-998920-1-8.
  • Kotopoulis, Spiros; Delalande, Anthony; Popa, Mihaela; Dimcevski, Georg Gjorgji; Gilja, Odd Helge; Postema, Michiel; Gjertsen, Bjørn Tore; McCormack, Emmet Martin. 2013. Ultrasound and microbubble enhanced therapy of orthotopic human pancreatic cancer in mice. Session 2, pages 45-47. In:
    • Nortvedt, Ragnar; Gilja, Odd Helge. 2013. MedViz Conference 2013. 146 pages. ISBN: 978-82-998920-1-8.
  • Mujic, Maja; Haugse, Ragnhild; Kotopoulis, Spiros; Sulen, Andre; Gilja, Odd Helge; Postema, Michiel; Gjertsen, Bjørn Tore. 2013. Ultrasound combined with microbubbles modulates signal transduction pathways in blood cells. Poster Abstracts, pages 119-120. In:
    • Nortvedt, Ragnar; Gilja, Odd Helge. 2013. MedViz Conference 2013. 146 pages. ISBN: 978-82-998920-1-8.
  • Delalande, Anthony; Kotopoulis, Spiros; Pichon, Chantal; Gjertsen, Bjørn Tore; Postema, Michiel. 2012. Microbubbles and cell interactions. Session 4, pages 53-54. In:
    • Dimcevski, Georg Gjorgji; Gilja, Odd Helge. 2012. MedViz Conference 2012. 104 pages. ISBN: 978-82-998920-0-1.
  • Mujic, Maja; Kotopoulis, Spiros; Delalande, Anthony; Enger, Marianne; Gilja, Odd Helge; McCormack, Emmet Martin; Postema, Michiel; Gjertsen, Bjørn Tore. 2012. Flow cytometic characterization and sorting of ultrasound contrast agents. Chapter 11, pages 171-183. In:
    • Kotopoulis, Spiros; Delalande, Anthony; Godø, Olav Rune; Postema, Michiel. 2012. Micro-acoustics in marine and medical research. 198 pages. ISBN: 978-82-303-1945-1.
  • Christoffersen, Thoralf; Gjertsen, Bjørn Tore; Engebråten, Olav; Guren, Tormod K. 2009. Signalhemmere. Kapittel 17, pages 226-249. In:
    • Dahl, Olav; Lehne, Gustav; Baksaas, Ingebjørg; Kvaløy, Stein Olav; Christoffersen, Thoralf. 2009. Medikamentell kreftbehandling. 495 pages. ISBN: 978-829923312-5.
  • Gjertsen, Bjørn Tore; Lorens, James. 2008. Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. Kapittel 16, pages 193-205. In:
    • Willard, Huntington F.; Ginsburg, Geoffrey S. 2008. Genomic and personalized medicine. Academic Press. 1478 pages. ISBN: 978-0-12-369420-1.
  • Gjertsen, Bjørn Tore; Vatne, Øystein; Nilsen, Arvid E. 1997. Hudsykdommer. 2. utgave. 312-338. In:
    • Arentz-Hansen, Cecilie; Moen, Kåre. 1997. Legevakthåndboken. Universitetsforlaget. ISBN: 82-00-41574-0.
  • Brustugun, Odd Terje; Mellgren, Gunnar; Gjertsen, Bjørn Tore; Bjerkvig, Rolf; Døskeland, Stein Ove. 1996. Sensitive and rapid detection of B-galactosidase expression in intact cells by microinjection of fluorecent substrate. In:
    • Slavik, J. 1996. Fluorecence microscopy and fluorescent probes.

More information in national current research information system (CRIStin)